Article

Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis.

Service d'Hématologie-Greffe, Saint-Louis Hospital, Université Paris 7-Diderot, Paris, France.
Bone marrow transplantation (impact factor: 3). 11/2010; 46(4):557-61. DOI:10.1038/bmt.2010.276 pp.557-61
Source: PubMed

ABSTRACT Allogeneic haematopoietic stem-cell transplantation (HSCT) is the only curative treatment for myelofibrosis. We retrospectively analyzed the outcome of patients who underwent allogeneic HSCT, 1994-2008, and the potential risk factors affecting non-relapse mortality (NRM), OS and relapse-free survival (RFS). A total of 39 patients, 15-65 (median 49) years old, diagnosed with primary (n=27) or secondary (n=12) myelofibrosis underwent HSCT (25 related and 14 unrelated). In ten patients, disease had transformed into acute leukaemia. Lille prognosis score was low for 9, intermediate for 16 and high for 14 patients. The conditioning regimen was myeloablative (MAC) for 15 and reduced-intensity (RIC) fludarabine-based for 24, with successful engraftment in 38 patients. A total of 31 patients developed grade I-IV GvHD; 19 developed chronic GvHD. The 3-year OS, RFS and NRM rates (95% confidence interval) were 60% (42-74), 54% (37-59) and 30% (30-45), respectively.

0 0
 · 
0 Bookmarks
 · 
38 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

14 patients
 
14 unrelated
 
31 patients
 
38 patients
 
39 patients
 
95% confidence interval
 
acute leukaemia
 
Allogeneic haematopoietic stem-cell transplantation
 
allogeneic HSCT
 
chronic GvHD
 
conditioning regimen
 
grade I-IV GvHD
 
Lille prognosis score
 
NRM
 
NRM rates
 
patients
 
potential risk factors
 
reduced-intensity
 
relapse-free survival
 
successful engraftment